Par Pharmaceutical Companies, Inc. has entered into a definitive merger agreement to be acquired by an affiliate of TPG in a transaction valued at $1.9 billion. Par shareholders will receive $50.00 in cash for each share of Par stock, representing a premium of approximately 37% over the closing share price on July 13, 2012. The agreement was approved by Par’s board of directors. Patrick G. LePore, Par’s chairman and chief executive officer, said, “We are excited about this tra...